ANI Pharmaceuticals executives will present at the J.P. Morgan Healthcare Conference on January 14, 2025, in San Francisco.
Quiver AI Summary
ANI Pharmaceuticals, Inc. announced that its President and CEO Nikhil Lalwani, CFO Stephen Carey, and CMO Dr. Mary Pao will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2025, at 2:15pm PST/5:15pm EST. The presentation will be available via a live and archived webcast on the company's website. ANI Pharmaceuticals is a biopharmaceutical company dedicated to developing, manufacturing, and commercializing effective therapeutics, with a focus on rare diseases and several therapeutic areas including ophthalmology and rheumatology, among others. For further details, visit their website.
Potential Positives
- ANI Pharmaceuticals will be represented by key executives at a prominent industry conference, which elevates the company's visibility among investors and industry peers.
- The participation in the J.P. Morgan Healthcare Conference indicates the company's commitment to engaging with stakeholders and showcasing its growth prospects.
- The webcast of the presentation will be accessible for 90 days, allowing for broader audience engagement and continued visibility post-presentation.
- ANI Pharmaceuticals' focus on diverse therapeutic areas positions it as a significant player in the biopharmaceutical industry, potentially attracting interest from investors looking for innovative companies in healthcare.
Potential Negatives
- The announcement of a presentation at a major healthcare conference may indicate that the company is seeking to enhance its visibility and investor interest, suggesting potential challenges in current market perception or performance.
- Lack of detailed updates on product pipeline or financial performance in the release could raise concerns among investors about the company's growth prospects and transparency.
- The timing of the presentation may coincide with heightened scrutiny in the biotech sector, which could present risks if the company is not performing well compared to its peers.
FAQ
What is ANI Pharmaceuticals' upcoming event?
ANI Pharmaceuticals will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025.
Who will represent ANI Pharmaceuticals at the conference?
Nikhil Lalwani, Stephen Carey, and Dr. Mary Pao will represent ANI Pharmaceuticals at the conference.
How can I access the webcast of the event?
The live and archived webcast will be available on ANI's website under the Investors section.
What is ANI Pharmaceuticals' primary mission?
ANI Pharmaceuticals is committed to "Serving Patients, Improving Lives" through innovative therapeutics.
How long will the webcast replay be available?
The replay of the webcast will be accessible for 90 days after the event.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ANIP Insider Trading Activity
$ANIP insiders have traded $ANIP stock on the open market 16 times in the past 6 months. Of those trades, 0 have been purchases and 16 have been sales.
Here’s a breakdown of recent trading of $ANIP stock by insiders over the last 6 months:
- STEPHEN P. CAREY (SVP & CFO) sold 7,500 shares.
- MEREDITH COOK (SR. VP, GENERAL COUNSEL & SEC.) has traded it 6 times. They made 0 purchases and 6 sales, selling 1,500 shares.
- KRISTA DAVIS (SVP, CHIEF HR OFFICER) sold 1,000 shares.
- NIKHIL LALWANI (PRESIDENT & CEO) has traded it 2 times. They made 0 purchases and 2 sales, selling 33,481 shares.
- CHRISTOPHER MUTZ (HEAD OF RARE DISEASE) sold 6,500 shares.
- MUTHUSAMY SHANMUGAM (HEAD OF R&D, COO-NOVITIUM OPS) has traded it 4 times. They made 0 purchases and 4 sales, selling 50,000 shares.
- CHAD GASSERT (SVP - CORP. DEV. & STRATEGY) sold 20,000 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ANIP Hedge Fund Activity
We have seen 121 institutional investors add shares of $ANIP stock to their portfolio, and 72 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GOLDMAN SACHS GROUP INC added 626,110 shares (+696.0%) to their portfolio in Q3 2024
- PACER ADVISORS, INC. added 565,910 shares (+23259.8%) to their portfolio in Q3 2024
- RUBRIC CAPITAL MANAGEMENT LP removed 547,129 shares (-90.6%) from their portfolio in Q3 2024
- JPMORGAN CHASE & CO added 340,854 shares (+159.3%) to their portfolio in Q3 2024
- MILLENNIUM MANAGEMENT LLC added 299,673 shares (+130.2%) to their portfolio in Q3 2024
- SOLEUS CAPITAL MANAGEMENT, L.P. added 269,000 shares (+inf%) to their portfolio in Q3 2024
- UBS GROUP AG added 254,514 shares (+796.0%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
PRINCETON, N.J., Dec. 30, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer; Stephen Carey, Chief Financial Officer; and Dr. Mary Pao, Chief Medical Officer, will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 2:15pm PST/5:15pm EST, in San Francisco.
The live and archived webcast will be accessible from the Company’s website at www.anipharmaceuticals.com , under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 90 days.
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Established Brands business. For more information, visit www.anipharmaceuticals.com .
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E:
[email protected]
Source: ANI Pharmaceuticals, Inc.
